title: Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial.
abstract: BACKGROUND
  Treatment of gonorrhea is complicated by widespread resistance of Neisseria gonorrhoeae to antimicrobial agents of choice, including decreased susceptibility to ciprofloxacin.
  
  
  OBJECTIVE
  To demonstrate the efficacy and safety of gatifloxacin, a novel 8-methoxy fluoroquinolone antibiotic, compared with ofloxacin in treating patients with uncomplicated gonococcal infection.
  
  
  METHODS
  In a double-blind, randomized (2:2:1), controlled trial, 340 men and 388 women with uncomplicated gonorrhea who were 16 years or older received a single oral dose of gatifloxacin (400 mg or 600 mg) or ofloxacin (400 mg). Primary analysis of efficacy was based on bacteriologic eradication from sites of infection. Secondary analyses examined clinical response and adverse event profiles.
  
  
  RESULTS
  Bacteriologic eradication rates for gatifloxacin in evaluable men with urethral gonorrhea were 99% (400 mg) and 100% (600 mg) versus 100% for ofloxacin (n = 117, 122, and 55, respectively; P = ns). Eradication rates in evaluable women with endocervical gonorrhea were 99% for both 400 mg and 600 mg gatifloxacin versus 100% for ofloxacin (n = 101, 104, and 55, respectively; P = ns). Eradication rates were 100% for both rectal (n = 43) and pharyngeal (n = 31) infection across all treatment groups. All three drug regimens were well tolerated and exhibited similar clinical response profiles.
  
  
  CONCLUSIONS
  Gatifloxacin is safe and effective as a single 400-mg or 600-mg dose for the treatment of uncomplicated gonorrhea. Similar efficacy rates were observed with the 400-mg and 600-mg doses. A single 400-mg dose can be recommended for treatment of uncomplicated gonorrhea.
authors: Washington University School of Medicine, St Louis, Missouri 63110, USA. bstoner@im.wustl.edu
authors: B P
authors: BP
authors: Stoner
authors: J M
authors: JM
authors: Douglas
authors: D H
authors: DH
authors: Martin
authors: E W
authors: EW
authors: Hook
authors: P
authors: P
authors: Leone
authors: W M
authors: WM
authors: McCormack
authors: T F
authors: TF
authors: Mroczkowski
authors: R
authors: R
authors: Jones
authors: J
authors: J
authors: Yang
authors: T
authors: T
authors: Baumgartner
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D015242:Ofloxacin / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015242:Ofloxacin; D000077734:Gatifloxacin